Abstract
Arterial stiffness is an independent predictor of cardiovascular events in a hypertensive population. Serum levels of matrix metalloproteinase (MMP)-9 are associated with arterial stiffness and predict cardiovascular risk. We investigated the role of MMP-9 polymorphism −1562C>T on blood pressure (BP) and arterial stiffness in a newly diagnosed hypertensive population. Untreated hypertensive patients (n=215, mean age 46±13 years) were studied. Supine BP, carotid-femoral pulse wave velocity (PWV) and augmentation index were assessed. Serum biochemistry and plasma MMP-9 concentrations were measured and genotyping performed following extraction of genomic DNA. BP, aortic PWV and serum MMP-9 levels were significantly higher in T-allele carriers of the −1562C>T polymorphism with a significant gene–dose effect (P<0.0001). In a stepwise regression model adjusting for known or likely determinants, the 1562C>T polymorphism emerged as an independent predictor of systolic BP (R2=0.25, P<0.0001), diastolic BP (R2=0.16, P<0.0001) and PWV (R2=0.47,P<0.0001). This is the first study to show the effect of MMP-9 polymorphism on BP and aortic stiffness in a hypertensive population. These results suggest that hypertensive patients carrying the T allele may be at increased risk of cardiovascular events.
Similar content being viewed by others
References
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J . Global burden of hypertension. Lancet 2005; 365: 217–223.
Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664–670.
Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–1241.
Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34: 1–4.
Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10–15.
Spinale FG . Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520–530.
Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380–384.
Longo GM, Xiong W, Griener TC, Zhao Y, Fiotti N, Baxter BT . Matrix metalloproteinase 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625–632.
Zhang B, Ye S, Hermann SM, Erikssson P, de Matt M, Evans A et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788–1794.
Derosa G, D'Angelo A, Ciccarelli L, Piccini MN, Pricolo F, Salvadeo S et al. Matrix metalloproteinase-2, and 9 and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227–231.
Marx N, Frolich JC, Siam L, Ittner J, Wierse G, Schmidt A et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283–288.
Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579–1585.
Yasmin, Wallace S, McEniery CM, Dakham Z, Pusalkar P, Mak-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscl Thromb Vasc Biol 2005; 25: 372.
Morgan AR, Zhang B, Tapper W, Collins A, Ye S . Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med 2003; 81: 321–326.
Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA . Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscl Thromb Vasc Biol 2004; 24: 1479–1484.
Yasmin, McEniery C, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscl Thromb Vasc Biol 2006; 26: 1799–1805.
Mahmud A, Feely J . Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118–1122.
Julius S, Shawna N . Sympathetic overactivity in hypertension. Am J Hypertens 1996; 9: 113S–120S.
Laurent S, Boutouyrie P, Lacolley P . Structural and genetic bases of arterial stiffness. Hypertension 2006; 45: 1050–1055.
McNulty M, Mahmud A, Spiers J, Feely J . Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 2006; 20: 867–873.
Galis ZS, Johnson C, Godin D, Magid R, Shipley MJ, Senior RM et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002; 91: 852–859.
Skalska A, Gasowski J, Cwynar M . The relationship between pulse wave velocity and indexes of collagen synthesis in hypertensive patients, according to the level of systolic blood pressure. J Hum Hypertens 2005; 19: 731–735.
Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson JH et al. Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature 1994; 30: 555–557.
Schonbeck U, Mach F, Libby P . Generation of biologically active IL-1b by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1b processing. J Immunol 1998; 161: 3340–3346.
Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ . Vasoactive drugs influence aortic augmentation index independently of pulse wave velocity in healthy men. Hypertension 2001; 37: 1429–1433.
Mahmud A, Feely J . Adiponectin and arterial stiffness. Am J Hypertens 2005; 18: 1543–1548.
Cowley Jr AW . The genetic dissection of essential hypertension. Nat Genet 2006; 7: 829–840.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, S., Feely, J., Spiers, J. et al. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 21, 861–867 (2007). https://doi.org/10.1038/sj.jhh.1002244
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002244
- Springer Nature Limited
Keywords
This article is cited by
-
Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme
BMC Cardiovascular Disorders (2021)
-
Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness
Neurological Sciences (2016)
-
Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension?
Cytotechnology (2015)
-
Genetic Determinants of Arterial Stiffness
Journal of Cardiovascular Translational Research (2015)
-
Effects of N-Acetylcysteine on the Cardiac Remodeling Biomarkers and Major Adverse Events Following Acute Myocardial Infarction: A Randomized Clinical Trial
American Journal of Cardiovascular Drugs (2014)